Decreased neurokinin B as a risk factor of functional hypothalamic amenorrhea

Figures & data

Figure 1. Serum NKB concentrations in patients with FHA and in healthy control subjects.

Figure 2. Serum NKB concentrations in patients with FHA with normal and decreased BMI.

Table 1. Results of hormonal and metabolic profiles measured in the FHA and control groups.

Measured parameter	FHA	Control group	p value
	Mean ± SD	Mean ± SD
FSH [mIU/mL]	4.59 ± 2.06	5.68 ± 1.93	<0.001
LH [mIU/mL]	1.98 ± 1.43	15.55 ± 11.7	<0.001
E2 [pg/mL]	18.77 ± 11.51	210.17 ± 120.4	<0.001
Prolactin [ng/mL]	8.54 ± 5.13	15.26 ± 5.72	<0.001
Testosterone [ng/mL]	0.31 ± 0.16	0.42 ± 0.19	<0.001
DHEA-S [µmol/L]	7.24 ± 2.8	7.55 ± 3.1	0.60
Morning cortisol [nmol/L]	400.95 ± 129.06	367.29 ± 135.86	0.02
TSH [µIU/mL]	1.88 ± 0.90	2.41 ± 0.90	<0.001
fT4 [ng/dL]	1.12 ± 0.17	1.29 ± 0.16	<0.001
Body mass index [kg/m²]	19.64 ± 2.37	21.89 ± 2.55	<0.001
Insulin [mU/mL]	5.37 ± 3.0	7.84 ± 3.56	<0.001
Glucose [mg/dl]	78.61 ± 10.06	79.90 ± 8.00	0.25
HOMA-IR	1.06 ± 0.64	1.57 ± 0.79	<0.001
Total cholesterol [mg/dL]	183.84 ± 44.66	167.33 ± 32.34	0.023
HDL-C [mg/dL]	72.15 ± 16.16	64.31 ± 12.87	0.007
LDL-C [mg/dL]	98.23 ± 34.43	103.79 ± 33.95	0.537
Triglycerides [mg/dL]	75.84 ± 27.54	75.87 ± 33.96	0.823
Neurokinin B [ng/L]	628.35 ± 324.92	721.41 ± 337.57	0.002